Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Flying Brands says next phase of trials for Stone Checker, kidney stones treatment can start ahead of schedule

In an operational update, the medical services and software company said a multi-centre investigator led study comprising data from 607 patients at two academic university hospitals has now been completed
Medical tests
Flying Brands said the results from the two institutions with their different kidney stone treatment protocols have reproduced and validated the results from its preliminary study

Flying Brands Ltd (LON:FBDU) said analysis of two studies for their Stone Checker, kidney stones treatment have reproduced and validated the results from a preliminary study, meaning the next phase of investigation can start ahead of schedule.

In an operational update, the medical services and software company said a multi-centre investigator led study comprising data from 607 patients at two academic university hospitals - Oxford University Hospital, Oxford, UK and Peking Union Medical College Hospital, Beijing, China - has now been completed.

WATCH: Stone Checker's Nick Stevens 'absolutely delighted' with early completion of kidney stone studies

The group added that Internal quality review and expert advice from a medical statistician has concluded that the quality of the completed 607 patient data set makes it unnecessary to extend the data collection to the 800 patients study originally planned and consequently the data is now being analysed ahead of schedule.

Flying Brands said the results from the two institutions with their different kidney stone treatment protocols have reproduced and validated the results from its preliminary study.

Next phase of statistical optimisation can now start ahead of schedule

It added, therefore, the next phase of statistical optimisation can now start ahead of schedule and will assess the best predictive model using multi-variate analysis.

This is due to be completed by the end of July 2017.

READ: Flying Brands boss Trevor Brown lifts stake

The group said, on the basis of the strong early results, Stone Checker has contracted with a specialist medical imaging software development company in North America to produce medical device quality software in the formats of both PACS plugin and a separate cloud-implementation.

In parallel, it added, the contracted North American software development company will also undertake regulatory work to CE mark the software within a medical standards quality process and then manage the submission for approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration (FDA).

The target date for CE marking is December 2017 and for FDA approval is Q2 2018.

Stone Prevent also progressing

Flying Brands said work has also progressed on its Stone Prevent product, with development continuing, led by a leading consultant chemical pathologist based at a UK University Hospital.

They said a proof of principle phase has been completed and a unique clinical algorithm is in development which aims to simplify the reporting of 24-hour urine tests.

The group said the results will give doctors and patients a convenient and clinically useful service and the information may help to reduce the rate of kidney stone recurrence, and further work in the next weeks will identify logistic partners.

Flying Brands said Stone Checker will be presenting the clinical algorithm at The British Association of Urological Surgeons (BAUS) Section of Endourology Annual Meeting in Leeds on September 8 2017 and will be looking for partners to help commercialise the Stone Prevent product.

View full FBDU profile View Profile

Flying Brands Ltd Timeline

Related Articles

H&T Pawnbrokers store
November 15 2017
“We have delivered a strong trading performance during the second half in the key segments of Pawnbroking, Retail and Personal Loans”
Flying Brands
March 07 2018
Flying Brands has signed a deal for the sale and distribution of its StoneChecker software in South Korea

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use